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Abstract
Introduction: Acute heart failure syndrome (AHFS) is one of the leading causes of hospital admission in the US. Tolvaptan is a vasopressin 
V2 receptor antagonist that blocks the effect of arginine vasopressin (AVP) in reabsorbing water from the collecting ducts of the nephrons 
in congestive heart failure.
Aims: To review the evidence for utilizing tolvaptan in the treatment of AHFS.
Evidence review: Several clinical trials have sought to assess the clinical effects of tolvaptan in heart failure. Compared with placebo, 
tolvaptan has been shown to reduce bodyweight and improve serum sodium in patients with AHFS without worsening renal function. 
Tolvaptan appeared to be well tolerated with a good safety profile. It caused a significant reduction in pulmonary capillary wedge pressure 
compared with placebo, but has yet to demonstrate reversal of cardiac remodeling. A large-scale mortality trial showed no differences 
in long-term mortality rates between tolvaptan and placebo, although early symptom relief was apparent with tolvaptan and lower   
diuretic use.
Place in therapy: Tolvaptan has shown to be safe and effective in treating congestion in AHFS. Free water excretion in fluid-overloaded 
patients vulnerable to cardiorenal compromise with standard diuretic therapy makes V2 vasopressin receptor blockade an attractive 
adjunct to standard medical therapy aimed at reducing congestion in AHFS. 
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Core evidence place in therapy summary for tolvaptan as an addition to standard therapy in patients 
with acute heart failure syndrome
Outcome measure Evidence Implications
Patient-oriented evidence
Decrease in fluid balance and bodyweight Clear Consistent reduction in bodyweight and favorable 
fluid balance without detrimental electrolyte 
imbalance
Decrease in symptom burden Clear  Tolvaptan improves symptoms in patients with acute 
heart failure syndrome
Safety and tolerability Clear Tolvaptan has an acceptable tolerability profile
Improvement in quality of life Substantial Improved symptoms balances troublesome  
side effects
Neutral effects in morbidity and mortality Substantial Tolvaptan has not been associated with decreased 
mortality compared with placebo
Disease-oriented evidence
Improvement in serum sodium Clear Tolvaptan improves serum sodium concentrations. 
Hyponatremia is a marker of poor outcome in  
heart failure
Increased urine output Clear Relieves congestion
Preservation of renal function Clear Tolvaptan does not worsen renal function; worsening 
renal function is a known predictor of mortality in 
heart failure
Neutral effect on ventricular volumes  Substantial Drugs with mortality benefit in heart failure have 
generally shown to halt the process of remodeling
Improvement in hemodynamic measures Substantial Tolvaptan reduces pulmonary capillary wedge 
pressure and congestion
Economic evidence
Cost effectiveness No evidenceTolvaptan | place in therapy review
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Scope, aims, and objectives
Arginine vasopressin (AVP) has long been known to play a central 
role in the pathophysiology of congestive heart failure. Tolvaptan 
is an oral, nonpeptide vasopressin V2 receptor antagonist that 
blocks the effects of AVP on renal collecting tubules, resulting in 
aquaresis and resolution of hyponatremia. The objective of this 
article is to review the available evidence for the use of tolvaptan 
in acute heart failure syndrome (AHFS), and includes results from 
several clinical studies. We also provide an overview of AHFS, 
its economic impact, and current treatment options to put into 
perspective what tolvaptan may provide. 
Methods
A literature search was conducted on October 4, 2007 in several 
databases using the search strategy stated below:
•   Ovid  Medline®  (http://gateway.uk.ovid.com/gw2/ovidweb.cgi): 
1950 to September 4, 2007. Search strategy (1) “tolvaptan”; (2) 
“tolvaptan” with CAS registry #; (3) “heart failure, congestive/ 
or edema, cardiac/” as mesh head; and (4) “((Heart or cardiac 
or myocard :) adj15 fail :)”. Search results were then crossed by 
searching for (1 or 2) and (3 or 4). The results were limited to 
English language resources
•   EMBASE  (http://gateway.tx.ovid.com/gw1/ovidweb.cgi):  1980 
to 2007 week 39 and EMBASE drugs and pharmacology 1980 
to 4th Quarter 2007. Search strategy (tolvaptan and CHF) OR 
tolvaptan and ((heart or cardiac or myocard :) adj15 fail :) limiting 
results to English language resources
•   All  evidence  based  medicine  reviews,  including  Cochrane 
DSR, ACP Journal Club, DARE, and CCTR. Search strategy 
“tolvaptan”
•   BIOSIS search (http://etextb.ohiolink.edu/bin/gat.exe). Search 
strategy (tolvaptan AND chf) AND (english.la.) OR ((tolvaptan 
AND fail$) AND (myocard$ OR cardiac OR heart)) AND (english.
la.).  The  results  were  crossed  with  (tolvaptan  AND  “14506”) 
AND (english.la.)
•   National  Guidelines  (www.guidelines.gov).  Search  strategy 
“tolvaptan”
•   Clinical Trial Registry (www.clinicaltrials.gov). Search strategy 
“tolvaptan”
•   NHS HTA (www.ncchta.org). Search strategy “tolvaptan”
•   Web of Science: 1980+ (Science Citation Index, Social Sciences 
Citation  Index  &  Arts  &  Humanities  Citation  Index).  Search 
strategy: “tolvaptan AND (CHF OR ( myocard* SAME fail*) OR 
(heart SAME fail*) OR (Cardiac SAME fail*)
•   SCOPUS (www.scopus.com). Search strategy “tolvaptan”
•   Cardiosource  Plus  (www.cardiosourceplus.com).  Search 
strategy “tolvaptan”
After removal of duplicates a total of 97 citations were identified 
from the above search engines, journals, and websites. Records 
were reviewed manually and 89 citations were excluded because 
of  tolvaptan  use  beyond  the  setting  of  heart  failure,  animal 
studies, or nonsystematic reviews. The remaining records were 
then classified into five classes of evidence based on the design 
of the study, with Level 1 evidence representing the strongest 
level of evidence and Level 5 representing the weakest evidence 
as summarized in Table 1.
Disease overview
The prevalence of heart failure in the US is estimated at more than 
5 million, with an incidence approaching 10 per 1000 in persons 
older than 65 years of age (Rosamond et al. 2007). Over the past 
30 years, the rate of hospitalizations for AHFS has increased from 
399 000 in 1979 to 1099 000 in 2004: an astounding increase 
of  175%  (Rosamond  et  al.  2007).  Data  from  ambulatory  care 
departments, hospital outpatient clinics, and emergency room 
admissions  between  1999  and  2000  documented  more  than   
3400 000 encounters due to AHFS. Naturally, this all translates 
into costly care. In the US, the overall cost of heart failure in 
2007 was $US33.2 billion (Rosamond et al. 2007). Similarly, data 
from European countries show that more than half of the cost of 
managing heart failure is related to inhospital expenses (Berry et 
al. 2001).
Over the past few decades, better understanding of the underlying 
pathophysiology has led to significant change in the treatment 
of  chronic  heart  failure,  and  the  targeting  of  neurohormonal 
abnormalities  that  drive  disease  progression.  Drugs  inhibiting 
the  renin-angiotensin-aldosterone  (RAAS)  and  sympathetic 
nervous systems have become the standard of care following 
several landmark clinical trials demonstrating their effectiveness. 
However, few drugs have been developed in the setting of AHFS, 
which  is  arbitrarily  defined  as  an  acute  onset  of  worsening 
signs and symptoms of heart failure requiring medical attention 
(Gheorghiade  &  Mebazaa  2005).  This  decompensated  state 
has long been recognized as the “congestion” presentation of   
heart failure. 
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Number of records
Category Full papers Abstracts
Initial search 97 7
records excluded 89 5
records included 8 2
Additional studies identified 0 0
Level 1 clinical evidence 0 0
Level 2 clinical evidence (RCT) 6 1
Level ≥3 clinical evidence
trials other than RCT 2 1
case reports 0 0
Economic evidence 0 0
For definition of levels of evidence see Editorial Information on inside back cover of journal 
or website http://www.coremedicalpublishing.com.
RCT, randomized controlled trial.
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We  have  learned  a  tremendous  amount  regarding  the 
contemporary  management  of  AHFS  from  the  large   
187 565 patient Acute Decompensated Heart Failure National 
Registry (ADHERE) (Adams et al. 2005), and the Euroheart Failure 
Survey  II  (Nieminen  et  al.  2006).  The  diagnosis  of  AHFS  is  a 
combination of clinical presentations (especially with worsening 
signs and symptoms of congestion), often in conjunction with 
verification by diagnostic testing in the majority of cases. Patients 
suspected  as  having  AHFS  often  carry  a  preexisting  cardiac 
condition, and evaluation of cardiac function is appropriate to 
categorize the heart failure type (systolic or diastolic heart failure) 
and to characterize the severity of the disease. However, it is 
important to point out that this categorization is largely historic: 
the majority of evidence-based treatment strategies have focused 
on  patients  with  left  ventricular  systolic  dysfunction.  Recent 
adoption of natriuretic peptide testing as an aid to the diagnosis 
of heart failure in the acute setting has been proven to enhance 
diagnostic accuracy and appropriateness in clinical management 
and improve clinical outcomes (Maisel 2003; Mueller et al. 2004; 
Moe et al. 2007). Guidelines also emphasize that interpretation 
of the natriuretic peptide values should be in the context of all 
available clinical data bearing on the diagnosis of heart failure.
Hospital admissions have been recommended in patients where 
more intensive diagnosis and management are warranted: those 
with hypotension, worsening renal function, altered mental status, 
severe  dyspnea  with  respiratory  compromise,  hemodynamic 
compromise  from  congestion  or  underlying  cardiac  diseases 
(ischemia,  arrhythmia),  or  severe  electrolyte  disturbances. 
Hospitalization  should  also  be  considered  in  new  onset  heart 
failure with significant congestion. 
Table 2 outlines the appropriate treatment goals for AHFS.
Pathophysiology
The underlying pathophysiology of AHFS is complex and poorly 
understood  (Figure  1),  which  may  explain  why  the  search  for 
effective drug therapy is challenging. It is, however, becoming 
more and more clear from intracardiac monitoring device data 
and narrative analyses that the acuity of AHFS can extend beyond 
2–3 weeks prior to the date of hospital admission (Schiff et al. 
2003;  Yu  et  al.  2005).  Several  well-recognized  and  potentially 
preventable precipitating factors have been identified over the 
years.  These  include  medication  and  dietary  nonadherence, 
use  of  harmful  medications,  infections,  anemia,  arrhythmias, 
uncontrolled hypertension, myocardial infarction, or emotional/
stressful events (Opasich et al. 2001; Fomiga et al. 2007). These 
observations may explain why in some cases AHFS develops due 
to a logistic problem (insufficient self care), while in other cases 
AHFS develops due to underlying biologic processes.
Renal involvement remains an important factor that drives the 
development of AHFS. The pivotal role of the kidney to remove 
salt  and  water  has  long  been  recognized.  Previously,  it  has 
been postulated that in the setting of diminished cardiac output 
leading  to  vascular  underfilling,  activation  of  neurohormonal 
systems, including the RAAS and the autonomic nervous system, 
are operative, and contribute to the kidneys’ ability to overdrive 
sodium retention leading to both salt and water retention and 
congestion (Packer 1992). Support for this hypothesis includes 
the propensity to develop AHFS in patients with marginal renal 
reserve as well as in patients with more advanced heart failure 
as a result of more diminished left ventricular ejection fraction 
(LVEF) or low cardiac output. This is also the primary basis for the 
effectiveness of loop diuretic therapy in volume-overloaded states, 
where enhancing the urinary removal of sodium (natriuresis) can 
lead to effective relief of congestion.
Recent observations have provided evidence that diastolic rather 
than systolic dysfunction is the driving factor in the progression 
of AHFS (Gandhi et al. 2001). This is consistent with observations 
that the majority of patients presenting with AHFS in ADHERE 
had preserved blood pressure, with almost 50% experiencing 
relative hypertension (systolic blood pressure beyond 140 mmHg) 
(Adams et al. 2005).
Current treatment options
While  several  professional  societies  have  published  extensive 
guidelines  for  the  management  of  chronic  heart  failure,  there 
are only two major guidelines available for AHFS: the European 
Society of Cardiology (ESC) guidelines (Nieminen et al. 2005) and 
the  Heart  Failure  Society  of  America  guidelines  (HFSA  2006). 
However, both guidelines have comparatively limited evidence 
available  to  direct  thorough  support  for  current  treatment 
strategies, in part because many treatment strategies preceeded 
the era of large-scale randomized controlled trials to justify their 
broad adoption. 
The primary aims of therapy have not evolved beyond (1) the 
reduction of congestive state with salt and water removal; and 
(2)  correction  of  underlying  hemodynamic  derangements  by 
either unloading the failing ventricle or by overdriving inotropy. 
A more contemporary secondary aim of AHFS therapy relates to 
the preservation of renal function. Table 3 provides an evidence-
based summary of currently approved AHFS therapy.
Relieving congestion
At present, diuretics are the mainstay of therapy in acute heart 
failure to reduce volume overload that results in congestion. This 
strategy is almost reflexive in the acute care setting once the 
diagnosis of AHFS is established. However, the ADHERE registry 
has suggested that there may be adverse effects from treatment 
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   Table 2 |   Treatment goals for patients admitted with AHFS 
(HFSA 2006, with permission)
Improve symptoms, especially congestion and low output syndromes
Optimize volume status
Identify etiologies and precipitating factors
Optimize chronic oral therapy
Minimize side effects
Identify patients who might benefit from revascularization
Educate patients concerning medications and self assessment of  
heart failure
Consider and, where possible, initiate a disease management program
AHFS, acute heart failure syndrome.Tolvaptan | place in therapy review
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with intravenous loop diuretics in patients who present with AHFS 
(Fonarow et al. 2005). It is also important to point out that few 
contemporary  prospective  clinical  trials  have  been  conducted 
to better understand the best strategy of use for these agents, 
appropriate doses, and routes of administration, as well as the 
most appropriate goals of therapy.
Recently,  there  has  been  resurgence  in  the  concept  of 
mechanical removal of salt and water by means of ultrafiltration. 
Newer and simpler devices have generated potential to utilize 
the  ultrafiltration  strategy  beyond  traditional  dialysis  settings, 
while  maintaining  the  amount  of  salt  and  solute  removal. 
The  Ultrafiltration  versus  Intravenous  Diuretics  for  Patients 
Hospitalized for Acute Decompensated Heart Failure (UNLOAD) 
study  showed  that  venovenous  ultrafiltration  produced  more 
weight loss at 48 hours, but no greater improvement in dyspnea 
or  changes  in  natriuretic  peptide  levels  when  compared  with 
loop diuretics in patients with AHFS (Costanzo et al. 2007). The 
effects of this approach in terms of safety and efficacy remain to 
be determined, although in UNLOAD the ultrafiltration arm was 
associated with fewer adverse clinical events at long-term follow-
up (Costanzo et al. 2007).
Unloading the ventricle
Vasodilators are another class of drugs used for the treatment of 
AHFS, which include nitroglycerin, nitroprusside, and natriuretic 
peptides.  Although  useful  in  the  acute  setting  to  counteract 
compensatory  arterial  vasoconstriction,  hypotension  and  renal 
insufficiency are potential adverse effects. Of the above mentioned 
drugs, nitroglycerin is a more balanced vasodilator, but its use 
has been limited by the development of tachyphylaxis, nitrate 
tolerance, and headaches. In the EuroHeart Failure Survey, 32% 
of patients with AHFS in Europe received intravenous nitroglycerin 
during  their  hospitalization,  compared  with  only  10%  in  the 
ADHERE study in the US (Komajda et al. 2003). Nitroprusside 
is  a  potent  vasodilatory  agent  with  a  favorable  hemodynamic 
profile of predominantly afterload reduction, but requires invasive 
hemodynamic monitoring in the intensive care setting. Side effects 
include  thiocyanate  poisoning,  which  is  relatively  uncommon. 
Nesiritide is a recombinant form of endogenous B-type natriuretic 
peptide  with  vasodilator  properties.  In  the  Vasodilation  in  the 
Management of Acute Congestive Heart Failure (VMAC) study, 
nesiritide  showed  a  significant  acute  (3  hour)  improvement 
in  dyspnea  versus  placebo,  but  not  when  compared  with 
nitroglycerin (Abraham et al. 2005). However, the use of nesiritide 
has been dogged by conflicting evidence regarding its long-term 
safety profile and potential to worsen renal function (Sackner-
Bernstein  et  al.  2005).  The  effect  of  intravenous  angiotensin-
converting enzyme (ACE) inhibitors on clinical outcomes has not 
been studied in AHFS populations and the use of these agents is 
not recommended based on concerns of acute administration in 
the setting of post-infarction heart failure. 
Other vasodilators have been studied in the setting of AHFS but 
have yet to receive approval for use in the US. Levosimendan, 
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Acute critical myocardial injury
• Acute myocardial infarction
Afterload – chronotropy/inotropy/lusitropy mismatch
          • Hypertensive crisis
          • Arrhythmias, etc
Previous myocardial injury
Remodeling
Chronic heart failure
Precipitating condition
       • Anemia, thyroid disease, etc
Blood volume?
Vascular resistance?
Filling pressure?
Wall tension? 
Critical LV deterioration
Cardiac output? 
Myocardial oxygen consumption? Coronary perfusion?
Tachycardia Hypotension
Acidosis, radical load
Low cardiac output
Reduced renal blood flow
Hypertrophy
Remodeling
   • Ischemia
   • Fibrosis
   • Myocyte death
       • Apoptosis
       • Necrosis Neuroendocrine activation
    • Sympathetic nervous system
    • RAAS
    • ADH, endothein
Dysregulation of contractility
    • Frank Starling mechanism?
    • Force-frequency relationship?
    • Catecholamine refractoriness
Peripheral perfusion?
Fig. 1 | Pathophysiology of heart failure (with permission from Nieminen et al. Eur Heart J. 2005;26:384–416. Oxford University Press). 
ADH, antidiuretic hormone; LV, left ventricle; RAAS, renin angiotensin aldosterone system.Tolvaptan | place in therapy review
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a  calcium  sensitizer,  is  in  clinical  use  in  several  countries  in 
Europe, South America, and Asia. In the Randomized Multicenter 
Evaluation of Intravenous Levosimendan Efficacy versus Placebo 
in  the  Short-Term  Treatment  of  Decompensated  Heart  Failure 
(REVIVE)–2  data,  levosimendan  resulted  in  a  favorable  effect 
on the primary endpoint (a clinical composite of clinical status 
assessment and major clinical events at 6 hours, 24 hours, and 
5 days), but was associated with a higher incidence of adverse 
events,  such  as  hypotension  and  arrhythmias  (Cleland  et  al. 
2006). The Survival of Patients With Acute Heart Failure in Need 
of Intravenous Inotropic Support (SURVIVE) study showed that 
short-term use of levosimendan and dobutamine was associated 
with similar postdischarge mortality at 180 days (Mebazaa et al. 
2007). Tezosentan, an intravenous endothelin receptor antagonist, 
has also been studied as a potent vasodilator in AHFS. However 
in the Value of Endothelin Receptor Inhibition with Tezosentan 
in  Acute  Heart  Failure  Studies  (VERITAS),  tezosentan  failed  to 
improve symptoms or long-term clinical outcomes (McMurray et 
al. 2007). 
Overdrive inotropy
Usage  of  inotropic  therapy  has  been  popularized  by  early 
pathophysiologic concepts of inadequacy of the failing heart to 
provide “forward” flow. However, several studies in both acute 
and chronic heart failure settings have highlighted the potential 
long-term mortality risk of inotropic therapy. Currently, inotropic 
therapy  such  as  dobutamine  (catecholamines)  or  milrinone 
(phosphodiesterase-3  inhibitors)  are  restricted  to  end-stage, 
low cardiac output heart failure patients refractory to standard 
medical  therapy,  as  routine  administration  in  AHFS  has  been 
associated with poor outcomes in various clinical trials (Cuffe 
et  al.  2002).  Although  dobutamine,  dopamine,  and  milrinone 
improve hemodynamics, this improvement is often associated 
with significant adverse effects that include hypotension, atrial 
and  ventricular  arrhythmias,  and  possibly  increased  post-
discharge mortality.
Unmet needs
Despite the large number of patients admitted every year for 
AHFS and the promise of several drug therapies with the launch 
of large-scale clinical trial investigations, the current treatment 
strategy has yet to differ substantially from that of a few decades 
ago. Intravenous loop diuretics remain the mainstay of therapy 
mainly  due  to  their  effectiveness  in  relieving  symptoms  of 
AHFS and their low cost. However, there has been increasing 
recognition of the potential hazards of cardiorenal compromise 
that overzealous use of acute or chronic loop diuretic therapy 
may cause (Neuberg et al. 2002). Another often accepted but 
poorly defined risk is the contribution of electrolyte disturbance 
during acute administration of aggressive loop diuretic therapy 
with  AHFS  admissions.  Diuretic  therapy  has  well-recognized 
side effects including electrolyte abnormalities, renal impairment, 
and neurohormonal activation (Bayliss et al. 1987).
What  is  more  alarming  is  that  our  current  strategy  is  not  as 
effective when symptom relief is the only measure of treatment 
success. Results from the ADHERE registry show that at least 
20% of patients with acute decompensated heart failure have no 
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Drug or class Evidence Indication Main adverse effects
Loop diuretics Never evaluated in large-scale randomized 
clinical trials
AHFS to relieve congestion Hypotension, electrolyte abnormalities, 
and worsening renal function
Vasodilators
     nesiritide Improves hemodynamics and reduces 
dyspnea, neutral survival benefit (Abraham  
et al. 2005)
AHFS to improve symptoms Hypotension, potential of worsening 
renal function
     nitrates High-dose isosorbide dinitrate more effective 
than furosemide in controlling severe 
pulmonary edema (Cotter et al. 1998)
First-line therapy for AHFS with 
adequate blood pressure 
Hypotension, headaches, 
development of nitrate tolerance
     sodium nitroprusside Favorable hemodynamic effects (Guiha et 
al. 1974), no data on survival benefit, may 
increase risk in post-MI patients (Cohn et al. 
1982)
Severe AHFS, hypertensive crisis Hypotension, cyanide toxicity, 
accumulation in renal insufficiency
Inotropes
     dopamine/dobutamine Shown to improve symptoms in small scale 
studies (Liang et al. 1984)
AHFS with hypotension and peripheral 
hypoperfusion 
Tachyarrhythmias, may increase 
mortality
     milrinone No effect on duration of hospital stay or 
mortality (Cuffe et al. 2002)
AHFS refractory to diuretics and 
vasodilators with preserved blood 
pressure
Sustained hypotension and 
tachyarrhythmia
     levosimendan No mortality benefit, reduces symptoms 
(Cleland et al. 2007; Mebazaa et al. 2007)
AHFS Increased rate of atrial fibrillation and 
ventricular tachycardia
Ultrafiltration More weight reduction than loop diuretics 
(Costanzo et al. 2007)
AHFS resistant to diuretics, or 
cardiorenal syndrome
Invasive, loss of solutes, procedural 
complications
MI, myocardial infarction.
   Table 3 |   Current evidence-based therapies for acute heart failure syndrome (AHFS)Tolvaptan | place in therapy review
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change or an increase in bodyweight during their hospitalization, 
and 30% have some improvement but are still symptomatic at 
discharge (Adams et al. 2005). These observations highlight the 
need for effective drug therapy to improve management in this 
patient population. 
Clinical trials of AHFS therapy now look beyond symptomatic 
relief, but even reliable surrogate markers such as bodyweight 
reduction and lowering natriuretic peptide levels have yet to be 
widely accepted due to their inconsistent relationship with long-
term clinical outcomes. 
Clinical evidence with tolvaptan
AVP is a neurohypophysial peptide hormone synthesized in the 
supraoptic and paraventricular nuclei in the hypothalamus and 
released by the posterior pituitary primarily for the maintenance 
of plasma osmolality through renal free water regulation (Lee et 
al. 2003). AVP exerts its effects by three distinct receptors: the 
V1A receptor subtype is present on vascular smooth muscle cells 
where it mediates vascular constriction; V2 receptors are present 
predominantly in the kidney collecting tubules where they mediate 
free water reabsorption; V1B, or V3, receptors are found in the 
anterior pituitary and they mediate adrenocorticotropin release 
(Verbalis 2002). As expected, the role of fluid regulation primarily 
resides on the V2 receptor effects. Induction of intracellular cyclic 
AMP  triggers  trafficking  of  aquaporins-2  water  channels  from 
intracellular  vesicles  to  the  apical  plasma  membranes  of  the 
collecting duct cells of nephrons. These processes allow water 
to  be  reabsorbed,  leading  to  direct  water  retention.  Naturally, 
antagonism of vasopressin V2 receptors will directly affect this 
pathway of water reabsorption independent of electrolyte transfer, 
leading to free water removal or “aquaresis.”
The role of vasopressin in patients with heart failure has been 
studied as far back as 1968, when Yamane (1968) reported that 
50%  of  patients  with  advanced  heart  failure  have  increased 
vasopressin levels. These findings were confirmed in the early 
1980s  with  the  use  of  more  sensitive  radioimmunoassay 
measurements (Goldsmith et al. 1983). The attempt to develop 
safe and effective pharmacologic agents to block the effects of 
AVP has met challenges of poor bioavailability, short half-lives, 
and partial agonistic properties of various compounds (Schrier 
& Martin 1998). 
Recently  however,  several  nonpeptide  vasopressin  receptor 
antagonists  have  entered  clinical  development.  Tolvaptan,  an 
oral, once-daily, V2 receptor antagonist synthesized by Otsuka 
Pharmaceutical Co. Ltd, is the first compound to be developed. 
Other  V2  receptor  antagonists,  lixivaptan  (developed  by 
CardioKline, Inc) and satavaptan (developed by Sanofi-Aventis) 
are undergoing late-stage clinical trials. Conivaptan (Vaprisol®, 
developed  by  Astellas  Pharma  US,  Inc.),  an  intravenous  dual 
V1A/V2  receptor  antagonist  is  the  only  vasopressin  receptor 
antagonist currently approved by the FDA for use in the US. The 
debate regarding the pros and cons of V2 only blockade versus 
dual  V1A/V2  antagonism  has  been  outlined  in  a  recent  review 
article (Goldsmith 2006). Table 4 summarizes the clinical studies 
conducted on tolvaptan in patients with heart failure.
Decrease in fluid balance and bodyweight 
Measurement of daily weight is used as an indicator of total body 
volume and effectiveness of diuresis in patients hospitalized with 
AHFS. Therefore, changes in bodyweight have been of primary 
interest  in  assessing  the  effectiveness  of  tolvaptan  in  treating 
congestion. In an evaluation investigating the effects of single-
dose tolvaptan administration in healthy individuals, increases 
were seen in mean serum sodium concentrations (4–6 mEq/L), 
plasma  osmolality  (~8  mOsm/kg),  and  free  water  clearance   
(~6 mL/min) throughout 0–24 hours, all independent of increasing 
dosage  (Shoaf  et  al.  2007).  Only  total  urine  volume  excretion   
(0–72 hours postdose) increased linearly with dose. Also, increase 
in plasma tolvaptan concentrations caused urine excretion rate 
to remain above baseline for a longer period of time (Shoaf et   
al. 2007). 
Reduction  in  bodyweight  was  the  primary  endpoint  measure 
in  one  of  the  first  studies  evaluating  the  effects  of  chronic 
administration of a vasopressin V2 receptor blocker in patients with 
heart failure. This study was a multicenter, double blind, placebo-
controlled trial that involved 254 patients with worsening heart 
failure, irrespective of LVEF (Gheorghiade et al. 2003). Patients 
were randomly assigned to receive tolvaptan 30, 45, or 60 mg 
or placebo for 25 days in an outpatient setting in addition to 
standard congestive heart failure therapy. The primary endpoint 
was bodyweight change over time, and secondary objectives 
included changes in peripheral edema, urinary sodium excretion, 
urine volume, and osmolality. All three doses of tolvaptan resulted 
in a statistically significant decrease in bodyweight at 24 hours 
compared with placebo; of interest, the effect did not appear 
to be dose dependent. This initial weight loss was maintained 
throughout the study without further reduction in weight beyond 
the first day. Urine output was also significantly greater in the 
tolvaptan groups compared with placebo when collected during 
the first day (3909, 4232, 4597, and 2328 mL for tolvaptan 30, 45, 
60 mg, and placebo, respectively) (Gheorghiade et al. 2003). 
The  favorable  effects  of  oral  tolvaptan  on  fluid  balance  and 
bodyweight were confirmed in the ACTIV in CHF trial, in which   
319  patients  with  LVEF  ≤40%  hospitalized  for  AHFS  were 
randomized to receive tolvaptan 30, 60, or 90 mg or placebo in 
addition to standard therapy (Gheorghiade et al. 2004). The major 
difference from prior studies was the need for hospitalization. 
The course of therapy included an inpatient period of 10 days, 
followed by a 7-week outpatient period. The inpatient endpoint 
was  change  in  bodyweight  24  hours  after  administration   
of  the  drug.  Bodyweight  decreased  significantly  in  the  first   
day  of  treatment  with  tolvaptan  (median  reduction  of  1.90, 
2.10, and 2.05 kg for tolvaptan 30, 60, and 90 mg, respectively) 
compared with placebo (0.6 kg). Bodyweight decreased further 
in  all  groups  during  hospitalization.  Changes  in  urine  output, 
a secondary endpoint of the trial, were significantly higher for 
all tolvaptan groups when compared with the placebo group, 
and  this  effect  was  also  maintained  throughout  the  period   
of hospitalization.
The  Efficacy  of  Vasopressin  Antagonism  in  Heart  Failure 
Outcome Study with Tolvaptan (EVEREST) clinical development 
program was a series of prospective, multicenter, international, Tolvaptan | place in therapy review
Core Evidence 2008;3(1)
randomized,  double-blind,  placebo-controlled  trials:  two 
identical  short-term  trials  (trials  A  and  B)  and  one  long-term 
outcome study. The primary endpoint of the short-term trials was 
a composite of change in global clinical status and bodyweight 
at  7  days  or  the  day  of  discharge,  whichever  was  earlier 
(Konstam  et  al.  2007).  EVEREST  included  patients  with  LVEF 
≤40% and known chronic heart failure admitted for AHFS who 
were randomized within 48 hours of hospitalization to receive 
fixed-dose  oral  tolvaptan  (30  mg/day)  or  matching  placebo.   
A total of 2048 patients were randomized in trial A (1018 patients 
in  the  tolvaptan  group  and  1030  in  the  placebo  group),  and   
2085 patients in trial B (1054 in the tolvaptan group and 1031 
in the placebo group). Mean bodyweight at day 1 was reduced 
by 1.76 kg in the tolvaptan group and by 0.97 kg in the placebo 
group (P<0.001). This effect was maintained long after the index 
hospitalization. In the short-term studies, tolvaptan resulted in a 
statistically significant improvement relative to placebo on the 
primary  endpoint,  the  composite  of  patient-assessed  global 
clinical status and bodyweight change at day 7 (P=0.0004) or 
discharge (P<0.0001). While the improvements in both scales 
were numerically in favor of tolvaptan, the change in average 
bodyweight at day 7 or discharge was significantly greater with 
tolvaptan  than  with  placebo  in  both  short-term  trials.  Mean 
weight  reductions  of  3.35  kg  versus  2.73  kg  (P<0.001)  and   
3.77 kg versus 2.79 kg (P<0.001) were seen at day 7 in each 
trial with tolvaptan and placebo, respectively (Gheorghiade et 
al.  2007).  Overall,  there  was  a  consistent  favorable  effect  on 
negative fluid balance and reduction in bodyweight as a result 
of the aquaretic effects of tolvaptan, and the evidence in this 
regard is clear.
Decrease in symptom burden
In the ACTIV in CHF trial, symptoms of heart failure improved 
in  all  patients  during  hospitalization;  however,  the  differences 
were not significant except for dyspnea (P=0.04) (Gheorghiade 
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Study aim Study design, patients,  
and treatment
Results References
Primary endpoint: bodyweight over time
Secondary endpoints: peripheral edema, 
urinary sodium excretion, urine volume, urine 
osmolality
DB RCT, n=254 with NYHA class II–III 
HF irrespective of EF;
Tol 30, 45, or 60 mg, or placebo for 
25 d
Statistically significant reduction in 
bodyweight at 24 h with Tol vs placebo 
Established safety and potential 
beneficial aquaretic effect of Tol in HF
Gheorghiade et al. 2003
Acute- and intermediate-term effects of Tol
Inpatient endpoint: bodyweight changes  
24 h after administration
Outpatient endpoint: worsening HF
DB RCT, n=319 hospitalized for 
worsening heart failure with EF ≤40% 
and NYHA class III–IV HF
Bodyweight decreased significantly 24 h 
after Tol vs placebo  
No significant difference in worsening HF 
between groups
Gheorghiade et al. 2004  
(ACTIV in CHF)
Effects of Tol in the absence of a diuretic on 
bodyweight, congestion, and serum sodium 
in HF
RCT, n=83 with NYHA class II–III HF; 
Tol 30 mg/d, Fur 80 mg/d,  
Tol 30 mg/d + Fur 80 mg/d,  
or placebo
Tol monotherapy and Tol + Fur resulted 
in significant reduction in bodyweight at 
1 wk vs Fur monotherapy and placebo
Reduction in leg edema, dyspnea, JVP, 
rales, and hepatomegaly observed in the 
Tol grop vs placebo
Udelson et al. 2002
Effect of Tol vs Fur on renal function RCT, n=14 with NYHA class II–III HF 
and EF ≤40%
Tol and Fur induced similar diuretic 
response; RBF increased with Tol, 
decreased with Fur; GFR was similar in 
the two groups
Costello-Boerrigter et al. 2006
Pharmacodynamics, pharmacokinetics, 
clinical safety of Tol 30 mg qd vs 15 mg bid
DB RCT, n=40; Tol 30 mg qd or  
15 mg bid for 7 d
Tol 30 mg qd =15 mg bid Hauptman et al. 2005
Primary endpoint: composite of change in 
global clinical status and bodyweight at  
7 days or the day of discharge (short-term 
trials); all-cause mortality and cardiovascular 
death or hospitalization for heart failure (long 
term trials)
DB RCTs (two short term, one long 
term), n=4133; Tol 30 mg/d  
or placebo
Significant weight reduction with Tol 
compared with placebo, significant 
improvement in dyspnea on day 1 of 
hospitalization compared with placebo
Gheorghiade et al. 2003; 
Konstam et al. 2007 (EVEREST)
Evaluate the effect of long term Tol on 
LVEDV and LV function
RCT, n=240 with HF; Tol 30 mg/d 
or placebo for 1 year; radionuclide 
ventriculography was performed at 
baseline, week 54, and 1 week after 
completion of therapy at week 55
No significant difference between 
changes in LVEDV index between the 
two groups 
Udelson et al. 2007a (METEOR)
Hemodynamic effect of Tol in patients with 
advanced heart failure due to  
systolic dysfunction
RCT, n=180 with stable NYHA class 
III or IV HF and LVEF ≤40%; single 
dose Tol 15, 30, 60 mg, or placebo 
during hemodynamic monitoring
All three doses of tolvaptan significantly 
affected the peak change in PCWP after 
3–8 h compared with placebo
Udelson et al. 2007b (ECLIPSE)
bid, twice daily; d, days; DB, double blind; EF, ejection fraction; Fur, furosemide; GFR, glomerular filtration rate; h, hours; HF, heart failure; JVP, jugular venous pressure; LV, left ventricle; LVEDV, 
left ventricular end diastolic volume; LVEF, left ventricular ejection fraction; NYHA, New York Heart Association; PCWP, pulmonary capillary wedge pressure; qd, once daily; RBF, renal blood flow; 
RCT, randomized controlled trial; Tol, tolvaptan; wk, week.
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et  al.  2004).  The  effects  of  tolvaptan  on  symptom  burden  of 
AHFS were further evaluated in EVEREST. In both short-term 
trials more patients reported day 1 improvements in dyspnea 
with tolvaptan than with placebo: 76.7% versus 70.6% in the 
first trial and 72.1% versus 65.3% in the other (both P<0.001).   
Day  1  patient-assessed  dyspnea,  bodyweight,  day  7  edema,   
and all secondary endpoints of this study improved significantly   
in  the  tolvaptan-treated  group.  However,  the  improvement  in 
edema  from  baseline  at  day  7  in  the  tolvaptan-treated  group 
reached  statistical  significance  in  only  one  of  the  two  short-
term  studies  (Gheorghiade  et  al.  2007).  Post-hoc  analysis 
showed  significant  improvement  in  dyspnea  and  rales  over 
the first 4 inpatient days, and in orthopnea and jugular venous 
distension in the first 3 inpatient days in patients treated with 
tolvaptan compared with placebo. Taken together, the evidence 
that tolvaptan provided incremental relief of symptom burden in 
hospitalized patients is relatively clear.
Safety and tolerability
At  this  stage,  there  is  adequate  evidence  that  tolvaptan  is 
a  relatively  safe  and  well-tolerated  drug  for  the  treatment  of 
heart failure. The most common side effects experienced with 
tolvaptan  have  been  generally  mild  and  associated  with  the 
pharmacologic  effect  of  the  drug  on  the  regular  feedback 
mechanism as a result of free water wasting; most commonly 
dry mouth, thirst, and polyuria (Gheorghiade et al. 2003, 2004; 
Konstam et al. 2007; Udelson et al. 2007a). In the ACTIV in CHF 
study, the most common side effect of tolvaptan was thirst, which 
was experienced by ~10% of patients (Gheorghiade et al. 2004). 
Even though 85% of patients in ACTIV in CHF reported adverse 
events, there were no significant differences in adverse events in 
patients receiving tolvaptan or placebo.
In EVEREST, use of tolvaptan was not associated with increased 
incidence of hypotension, tachycardia, renal failure, hypokalemia, 
hypomagnesemia,  or  liver  function  abnormalities  (Konstam 
et  al.  2007).  As  expected,  tolvaptan  increased  thirst  and  dry 
mouth (P<0.001). Hypernatremia occurred in 1.7% of tolvaptan 
recipients, compared with 0.5% of those taking placebo. Adverse 
events resulting in study drug discontinuation occurred in 6.5% 
and  5.5%  of  the  tolvaptan  and  placebo  groups,  respectively. 
The only adverse event resulting in study drug discontinuation 
that  was  significantly  different  between  the  two  groups  was 
thirst (n=7 versus n=0; P=0.02), even though these rates were 
very low for a large clinical trial (Konstam et al. 2007). Dry mouth 
resulted in drug discontinuation in four tolvaptan and none of the   
placebo patients.
Improvement in quality of life
Earlier  studies  revealed  no  significant  differences  in  the  self-
reported quality of life assessment between the tolvaptan and 
placebo  groups.  In  EVEREST,  a  prespecified  health-related   
quality  of  life  assessment  using  the  Kansas  City  Clinical 
Questionnaire  was  conducted,  and  showed  no  significant 
differences  between  the  treatment  groups  at  outpatient  visit   
week  1.  However,  during  the  last  scheduled  assessment  at 
study end, three out of the 10 study domains (quality of life, 
social limitation, and overall summary score) showed statistically 
significant changes favoring tolvaptan; the remaining domains 
also favored tolvaptan numerically but did not reach statistical 
significance (Konstam et al. 2007). These mixed results provide 
only some reassurance of the effect of tolvaptan in improving 
health  status,  which  has  to  balance  the  aforementioned 
troublesome side effects of thirst and dry mouth.
Neutral effects in morbidity and mortality
Admission  for  heart  failure  is  associated  with  significant  risk 
for  patients,  with  an  average  inhospital  mortality  rate  of  4% 
(Adams et al. 2005). Despite the emergence of new agents for 
the treatment of heart failure in the past few years, none have 
resulted in a substantial decrease in heart failure hospitalizations 
or mortality in this setting. The potential effects of tolvaptan on 
long-term morbidity and mortality have been generated from the 
concept of beneficial blockade of over-activated neurohormonal   
systems.  Indeed,  the  ACTIV  in  CHF  trial  had  two  primary   
endpoints  to  assess  both  the  acute-  and  intermediate-term 
effects  of  tolvaptan.  The  outpatient  endpoint  was  worsening   
heart failure (defined as rehospitalization, unscheduled visit for 
heart failure, or death at 60 days). The results did not show a 
significant difference in worsening heart failure between patients 
treated  with  tolvaptan  compared  with  placebo,  although  in 
post-hoc analysis event-free survival at 60 days was longer for 
the tolvaptan group, and total mortality was lower particularly 
in  patients  with  elevated  blood  urea  (BUN)  nitrogen  and  with 
severe  systemic  congestion  (Gheorghiade  et  al.  2004).  These 
findings were also confirmed in the one-year remodeling study, 
Multicenter  Evaluation  of  Tolvaptan  Effect  on  Remodeling 
(METEOR).  In  METEOR,  only  six  deaths  (5%)  occurred  in 
the  tolvaptan  group  compared  with  11  in  the  placebo  group 
(9.2%),  but  worsening  heart  failure  (defined  as  hospitalization 
or emergency department visit for heart failure or unscheduled 
treatment with intravenous diuretics) was approximately 28% in 
the tolvaptan group compared with 18% in the placebo group. 
An endpoint not previously specified, time to death or worsening 
heart failure, was significantly reduced in the tolvaptan group 
(P=0.03) (Udelson et al. 2007a).
In the long-term arm of EVEREST, 4133 patients were randomized 
to receive tolvaptan or placebo for a minimum of 60 days, in 
addition to standard therapy. Tolvaptan did not affect the two 
primary  endpoints  of  all-cause  mortality  and  cardiovascular 
death or hospitalization for heart failure, with a median follow-up 
of 9.9 months (Konstam et al. 2007) (Table 5). In the tolvaptan arm 
871 patients reached the composite endpoint of cardiovascular 
death or hospitalization for heart failure versus 829 patients in the 
placebo arm (42.0% versus 40.2%; P=0.55). Inhospital mortality 
was not different in the tolvaptan and placebo groups (2.4% and 
2.9%, respectively), and the corresponding all-cause mortality 
rates were 25.9% and 26.3% (Table 5).
With the paucity of new agents targeting AHFS (most of them 
challenged  with  questionable  long-term  safety  profiles),  the Tolvaptan | place in therapy review
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availability of evidence showing the lack of harm with add-on 
tolvaptan represents valuable and reassuring information for its 
use in this patient population. However, the neutral effects on 
morbidity and mortality were a slight disappointment following 
the favorable phase II data from ACTIV in CHF, where post-hoc 
evaluation suggested that 60-day therapy should lower mortality 
rates  in  tolvaptan-treated  patients  with  renal  dysfunction  or 
severe systemic congestion. 
Improvement in serum sodium
Hyponatremia  is  a  marker  of  poor  outcome  in  heart  failure 
(Kearney et al. 2002). Vasopressin receptor antagonists induce 
free water excretion by blocking the “antidiuretic” effect of AVP 
on  the  kidney  collecting  tubules,  resulting  in  an  increase  in 
plasma sodium. 
In the ACTIV in CHF trial, patients treated with tolvaptan had 
an increase in serum sodium after 24 hours of treatment, while 
serum  sodium  decreased  in  the  placebo-treated  group.  Also 
patients with serum sodium <136 mEq/L had a rapid increase 
and  often  normalization  in  concentration  that  was  maintained 
throughout the study (Gheorghiade et al. 2004). Post-hoc analysis 
of  ACTIV  in  CHF  revealed  that  the  60-day  mortality  among 
patients with improved serum sodium (increase of >2 mEq/L by 
the time of discharge) was 11.1%, compared with 21.7% in those 
patients whose serum sodium did not improve or improved by   
<2 mEq/L. After adjustment for covariates, improvement in serum 
sodium at discharge was a significant predictor of mortality at 
60  days  postdischarge.  In  EVEREST,  the  effects  of  tolvaptan 
on sodium were consistent with prior studies. Among patients 
with  baseline  serum  sodium  levels  <134  mEq/L,  mean  serum 
sodium concentrations increased by 5.49±5.77 mEq/L at day 7 
or discharge with tolvaptan, compared with 1.85±5.10 mEq/L in 
the placebo group (P<0.001). This effect was observed as early 
as day 1 and was maintained through 40 weeks of treatment 
(Konstam et al. 2007).
These findings are consistent with those of the recently published 
Study of Ascending Levels of Tolvaptan in Hyponatremia (SALT) 
trials, with corresponding improvements in mental component 
summary of the Short Form-12 Health Survey in hyponatremic 
patients  receiving  tolvaptan  compared  with  placebo  (Schrier 
et al. 2006). There was a lack of mortality or morbidity benefit 
favoring tolvaptan in EVEREST when analyzing the subgroup of   
patients with a serum sodium ≤137 mEq/L, thereby questioning 
the  clinical  significance  of  the  previous  studies’  findings.  The 
EVEREST investigators pointed out that only 8% of the population 
has baseline serum sodium levels <134 mEq/L (the prespecified 
exclusion criterion).
Effect on renal function
Worsening  renal  function  is  not  uncommon  in  acute 
decompensated heart failure, occurring in approximately 30% of 
patients (Cowie et al. 2006). Worsening renal function has been 
reported to be associated with increased all-cause mortality in 
patients with heart failure (Dries et al. 2000; Hillege et al. 2000). In 
fact, two out of three variables that are the strongest predictors 
of mortality in hospitalized AHFS patients involve renal function 
(Fonarow et al. 2005). In particular, higher doses of diuretics (often 
via the intravenous route) are administered during treatment of 
AHFS, which may place the patient at risk of worsening renal 
function (Butler et al. 2004). 
The renal effects of tolvaptan compared with furosemide have 
been  studied  in  a  small  mechanistic,  open-label,  randomized 
placebo-controlled  crossover  study  in  14  patients  with  heart 
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         Number of patients  (%)                         P value 
                               Hazard ratio 
    Tolvaptan  Placebo  (95%   Superiority  Noninferiority  
    (n=2072)  (n=2061)  confidence   
        interval)
Primary endpoints          
  all-cause mortality  537 (25.9)  543 (26.3)  0.98 (0.87–1.11)  0.68a  <0.001 
    
  cardiovascular death or   871 (42.0)  829 (40.2)  1.04 (0.95–1.14)   0.55a 
  hospitalization for heart failure         
Secondary endpoints         
  cardiovascular death or   1006 (48.5)  958 (46.4)  1.04 (0.95–1.14)  0.52a 
  hospitalization     
  incidence of cardiovascular   421 (20.3)  408 (19.8)    0.67b   
  mortality   
  incidence of clinical worsening  757 (36.5)  739 (35.8)    0.62b   
  of heart failure (death, hospitalization,      
  or unscheduled visits)
aBased on Peto-Peto-Wilcoxon test.
bBased on Cochran-Mantel-Haenszel test. 
   Table 5 |   Long-term primary and secondary outcomes in EVEREST (Konstam et al. 2007). Reproduced with permission from JAMA. 
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failure. As expected, tolvaptan administration was associated with 
equivalent diuresis without an increase in sodium and potassium 
excretion  (Costello-Boerrigter  et  al.  2006).  Tolvaptan  also 
increased renal blood flow, whereas furosemide administration 
resulted in decreased renal blood flow compared with placebo. 
Hence, free water excretion and preservation of renal blood flow 
make V2 receptor blockers attractive for the treatment of patients 
with AHFS. 
It  is  important  to  emphasize  that  the  use  of  tolvaptan  has   
been  tested  in  clinical  trials  as  an  addition  to  loop  diuretics   
instead  of  use  in  lieu  of  diuretics.  The  ACTIV  in  CHF  and   
EVEREST  trials  further  demonstrated  tolvaptan’s  ability 
to  reduce  congestion  without  causing  incremental  renal 
impairment.  In  EVEREST,  there  was  a  significant  difference 
favoring  tolvaptan  in  BUN  levels  between  the  two  groups  at 
day  1,  an  effect  that  tended  to  persist  long  after  discharge. 
At  day  7  or  discharge,  mean  BUN  levels  had  increased 
by  1.94±11.7  mg/dL  in  the  tolvaptan  group  and  by  3.30± 
12.16 mg/dL in the placebo group (P<0.001), with corresponding 
increases in mean serum creatinine levels of 0.08±0.31 mg/dL and 
0.03±0.35 mg/dL (P<0.001) (Gheorghiade et al. 2007). In post-
hoc analysis of the EVEREST trial, mean reduction in furosemide 
dosage  during  hospitalization  was  significantly  greater  in  the 
tolvaptan than the placebo group (–55.8 versus –42.9 mg/day; 
P=0.002) (Gheorghiade et al. 2007). This reduction in diuretic use 
may also be one mechanism by which a lowering of BUN was 
observed in the tolvaptan group, and less usage of furosemide 
may potentially decrease the commonly observed side effects 
associated with diuretic use, including worsening renal failure 
and electrolyte abnormalities.
Neutral effect on cardiac remodeling
Cardiac remodeling is now recognized as a key aspect in disease 
progression and has been viewed as a reliable surrogate for heart 
failure. The effects of tolvaptan on cardiac remodeling have been 
examined  in  the  METEOR  trial.  This  multicenter,  randomized, 
double-blind,  placebo-controlled  study  involved  240  patients 
with  mild-to-moderate  [New  York  Heart  Association  (NYHA) 
II–III]  chronic  heart  failure  with  LVEF  ≤30%,  and  compared 
oral tolvaptan 30 mg daily with placebo. The primary endpoint 
was left ventricular end diastolic volume (LVEDV) calculated by 
radionuclide ventriculography at baseline, week 54, and 1 week 
after completion of therapy at week 55. The results showed no 
significant difference in changes in LVEDV index between the two 
groups during 1 year of follow up (Udelson et al. 2007a). Also, 
there were no statistically significant differences in LVEF between 
tolvaptan and control groups (+1.32% versus +0.52%; P=0.16). 
Improvement in hemodynamic measures
Concerns  regarding  the  blockade  of  V2  receptors  generating 
overstimulation of V1A receptor effects on vasoconstriction have 
prompted extensive investigations on the hemodynamic effects 
of tolvaptan. It is reassuring that across all clinical studies, there 
has been no significant difference in changes of blood pressure 
or  heart  rate  between  the  tolvaptan  and  placebo  groups.  It 
is  important  to  emphasize  that  patients  with  systolic  blood 
pressure <90 mmHg were excluded in EVEREST and the systolic 
blood pressure cut off was even higher in the ACTIV in CHF trial   
(110 mmHg).
The  acute  hemodynamic  effects  of  tolvaptan  in  AHFS  were 
carefully evaluated in the Effect of Tolvaptan on Hemodynamic 
Parameters  in  Subjects  with  Heart  Failure  (ECLIPSE)  trial,  in 
which 180 patients with stable advanced heart failure (NYHA III–
IV, LVEF ≤40%) and pulmonary capillary wedge pressure (PCWP)   
≥18  mmHg  were  randomized  to  receive  a  single  dose  of 
tolvaptan 15, 30, or 60 mg or placebo during continuous central 
hemodynamic monitoring (Udelson et al. 2007b). Measurements 
were  obtained  for  12  hours  after  administration  of  the  drug   
while  patients  were  continued  on  standard  heart  failure 
medications  that  included  beta  blockers,  diuretics,  ACE 
inhibitors  and/or  angiotensin  receptor  blockers.  At  a  mean 
PCWP of 25 mmHg, all three doses of tolvaptan significantly 
affected  the  peak  change  in  PCWP  3–8  hours  after   
administration  (–6.38±0.62  mmHg  with  tolvaptan  15  mg, 
–5.67±0.70  mmHg  with  30  mg,  and  –5.71±0.65  mmHg  with 
60  mg;  P<0.05)  compared  with  placebo  (–4.16±0.67  mmHg), 
all  with  corresponding  increases  in  urine  volume  at  3  hours 
after  administration  (P<0.0001).  None  of  the  other  secondary 
outcome measures, including cardiac output, systemic vascular 
resistance,  heart  rate,  or  blood  pressure,  showed  significant 
changes between the tolvaptan and placebo groups (Udelson 
et al. 2007b).
Economic evidence and resource utilization
There have been no formal economic evaluations or assessments 
of  health  benefits  and  value  in  terms  of  quality-adjusted  life-
years  regarding  the  use  of  tolvaptan  in  AHFS.  Based  on  the 
outcome  analysis,  there  was  no  incremental  benefit  from 
reduced cardiovascular mortality or heart failure hospitalizations. 
Therefore,  further  justification  is  necessary  to  identify  patient 
subgroups that may offset the incremental cost of short-term 
symptomatic improvement.
Patient group/population
The current evidence for tolvaptan in AHFS is primarily restricted 
to the use of fixed-dose administration rather than alternative 
dosing approaches, such as dose adjustment based on clinical 
response.  Therefore,  this  may  not  preclude  the  subgroup 
of  volume-overloaded  patients  who  are  refractory  to  initial 
loop  diuretic  approach  or  those  with  significant  electrolyte 
or  cardiorenal  compromise.  While  tolvaptan  likely  provides 
beneficial reversal of hyponatremia, the clinical consequence of 
this resolution has yet to translate into clinical benefits, largely 
because of the relatively small patient population experiencing 
hyponatremia (only 8% in EVEREST). 
Furthermore,  morbidity  and  mortality  effects  of  tolvaptan 
have  only  been  evaluated  in  patients  hospitalized  with  signs 
and symptoms of congestion and reduced LVEF. While earlier 
studies on tolvaptan have included those with preserved LVEF   
(Table  6),  these  patients  were  excluded  from  larger  studies. Tolvaptan | place in therapy review
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There remains a lack of clinical trial data examining the role of 
tolvaptan, or indeed any other drug, in patients with preserved 
systolic  function  presenting  with  AHFS.  Based  on  our  current 
understanding  of  the  clinical  presentation  in  patients  with 
impaired versus preserved LVEF with AHFS, it is speculated that 
the  effects  of  tolvaptan  may  not  differ  considerably  between 
the  two  groups  but  further  studies  are  warranted  to  confirm   
these speculations.
Dosage, administration, and formulations
In  February  2008  the  European  Medicines  Agency  (EMEA) 
accepted a Marketing Authorization Application for tolvaptan to 
be used in the setting of worsening heart failure and hyponatremia. 
In June 2008, the FDA advisory panel recommended the approval 
of  tolvaptan  for  hypervolemic  or  euvolemic  hyponatremia. 
Tolvaptan can be given orally once daily and has been studied 
in  doses  ranging  from  15  mg  to  90  mg  daily.  Results  from 
clinical  trials  on  tolvaptan  have  not  shown  a  dose-dependent   
response and the frequency of adverse effects associated with 
tolvaptan was not increased with larger doses (Gheorghiade et al.   
2003, 2004). 
In EVEREST, tolvaptan was used as a 30 mg daily oral dose. There 
was no difference in the pharmacokinetics or pharmacodynamics 
of tolvaptan given as 30  mg once daily or 15 mg twice daily when 
these two doses were compared in a study of 40 heart failure 
patients in a double-blind fashion (Hauptman et al. 2005).
Conivaptan  is  a  dual  V1/V2  vasopressin  receptor  antagonist 
approved for usage in the US. While conivaptan is metabolized 
by cytochrome P450 3A4 (CYP3A4), the drug is also a potent 
inhibitor  of  CYP3A4.  Hence,  conivaptan  tends  to  increase 
plasma concentrations of coadministered drugs that are primarily 
metabolized by CYP3A4. When studied in oral form, conivaptan 
demonstrated multiple drug interactions, limiting its FDA approval 
to intravenous usage only.
As  tolvaptan  is  also  primarily  metabolized  by  the  CYP3A4 
pathway,  coadministration  of  calcium  channel  blockers, 
macrolide  antibiotics,  or  azole  antifungals  may  require  dose 
adjustments.  Coadministration  of  tolvaptan  has  been  shown 
to increase the maximal plasma concentration of ketoconazole 
by  248%.  However,  there  appear  to  be  no  drug  interactions 
between  tolvaptan  and  amiodarone  or  warfarin  (Wang  et  al. 
2003;  Shoaf  et  al.  2005).  Additional  studies  are  needed  to 
better assess the level of potential drug interactions associated   
with tolvaptan.
Place in therapy
Consistent  with  the  neurohormonal  hypothesis,  persistent 
neurohormonal  overactivation  may  drive  the  disease  process 
to further deterioration in patients with AHFS. As AVP is a true 
neurohormone, antagonism of AVP at the core of the development 
of  the  congestive  state  has  been  postulated  as  a  potential 
therapeutic target. However, the attempt to test this hypothesis 
with long-term antagonism of vasopressin V2 receptors failed to 
demonstrate incremental benefit over standard medical therapy 
including  loop  diuretics  and  neurohormonal  antagonists  in 
patients with heart failure.
The clinical trial program with tolvaptan has however produced 
an extensive safety profile, which is still an important assurance 
for healthcare providers using this agent. The current evidence 
suggests that tolvaptan is effective and long lasting in relieving 
congestion  by  free  water  removal  without  adversely  affecting 
kidney function. It is still most likely beneficial in patients with 
profound volume overload and existing or impending cardiorenal 
compromise,  either  in  the  setting  of  ineffective  diuresis  (as  in 
the case of ineffective weight loss and net urine output despite 
escalating doses of diuretics) or those with significant (or sensitive 
to) electrolyte abnormalities that would have further detrimental 
effects  with  overzealous  diuretic  therapy.  There  have  been  no 
randomized  control  trials  directed  to  these  specific  patient 
populations  to  generate  evidence  that  supports  the  potential 
benefits in these subgroups. As an aquaretic, tolvaptan is unlikely 
to replace loop diuretics unless it shows an incremental mortality 
benefit.  If  future  studies  confirm  the  neutral  mortality  effect 
of tolvaptan, its place in therapy will most likely fall within the 
treatment of congestion as an effective drug to reduce the adverse 
effects of high dose diuretic use or renal insufficiency in ADHF. 
Based  on  the  experience  of  EVEREST,  the  use  of  tolvaptan 
beyond  the  time  of  improvement  in  fluid  balance  and  clinical 
status is not justified. Furthermore, side effects of V2 receptor 
antagonists like thirst and mouth dryness will likely complicate 
long-term adherence to this medication. It is equally important 
to  point  out  that  with  the  lack  of  data  of  an  incremental   
mortality  benefit,  routine  use  of  V2  receptor  antagonists  will 
unlikely  be  justified  especially  with  the  likely  cost  differential 
compared  to  loop  diuretics,  except  in  aforementioned 
subgroups that would need careful confirmation of efficacies and   
economic justification. 
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